SinomedTrip
← Back to articles
5 min read
SinomedTrip Team

China's First PGT-Plus Baby Born at Tangdu Hospital, Xi'an

Tangdu Hospital achieved a national first — using integrated PGT-Plus technology to screen embryos for chromosomal and single-gene defects simultaneously, delivering a healthy baby.

Medically reviewed by SinomedTrip's clinical team

A National Breakthrough in Reproductive Medicine

"We can now test for everything in one step."

That's how Professor Wang Xiaohong, head of the Reproductive Medicine Center at Tangdu Hospital (Air Force Medical University, Xi'an), described the significance of a procedure her team recently completed — one that national, military, and regional media all covered.

For the first time in China, a baby has been born using PGT-Plus, an integrated preimplantation genetic testing technology that simultaneously screens embryos for chromosomal abnormalities, structural variants, and single-gene diseases — all in a single test cycle.

Tangdu Hospital PGT-Plus Technology

The Couple's Genetic Dilemma

The parents faced a combination of genetic risks that made natural conception extremely dangerous:

  • Chromosomal structural abnormality in one parent — dramatically increasing the chance of miscarriage or a child with unbalanced chromosomes
  • TBC1D24 gene mutations in both parents — a recessive condition linked to severe epilepsy, hearing loss, and neurological disability

Any pregnancy without genetic screening carried a high probability of serious outcomes. But traditional genetic testing approaches would require multiple separate test rounds — one for chromosomal balance, another for the specific gene mutation — adding months of time, thousands in cost, and significant emotional strain.

What Makes PGT-Plus Different

Professor Wang's team developed a unified protocol using high-throughput whole-genome sequencing that checks everything at once:

Traditional ApproachPGT-Plus
PGT-A for chromosome count — separate testAll three analyses from one embryo biopsy
PGT-SR for structural rearrangements — separate testSingle sequencing run covers everything
PGT-M for the specific gene mutation — separate testFaster results, higher accuracy, lower cost
3 rounds of analysis, weeks of waitingOne comprehensive report

The Result

The team performed IVF, biopsied the embryos at blastocyst stage, ran the integrated PGT-Plus analysis, and identified a healthy embryo — one that was chromosomally normal, structurally balanced, and free from two copies of the TBC1D24 mutation.

That embryo was transferred. Nine months later, a healthy baby was born.

The case was verified as China's first successful clinical application of integrated PGT-Plus technology, attracting coverage from CCTV and other major Chinese media outlets.

Why International Patients Choose China for IVF

China has quietly become one of the world's most advanced destinations for assisted reproduction, yet most international patients don't know this. Here's what the numbers show:

FactorChinaUnited StatesThailand
IVF success rate (under 35)55-65%50-60%45-55%
Wait time to start cycle2-4 weeks2-6 months2-4 weeks
Genetic screening technologyPGT-Plus availablePGT-A/M/SR (separate)PGT-A mainly
Average IVF cycle cost$4,000 - $7,000$15,000 - $25,000$8,000 - $12,000
PGT genetic screening$1,500 - $5,000$5,000 - $15,000$3,000 - $8,000

Reproductive Medicine Consultation

Who Should Consider PGT-Plus?

This technology is especially relevant for couples who:

  • Carry balanced translocations or inversions and have experienced recurrent miscarriage
  • Are known carriers of single-gene disorders — cystic fibrosis, thalassemia, sickle cell disease, spinal muscular atrophy, or conditions like TBC1D24
  • Have both chromosomal and single-gene risks — the exact scenario PGT-Plus was built for
  • Have failed previous IVF cycles due to genetically abnormal embryos
  • Want to minimize the number of test rounds and reduce overall treatment time

About Tangdu Hospital

Tangdu Hospital is one of two flagship hospitals of the Air Force Medical University in Xi'an:

  • Reproductive Medicine Center led by Professor Wang Xiaohong, a nationally recognized specialist in PGT and complex IVF cases
  • Among the earliest hospitals in China to offer third-generation IVF with comprehensive genetic testing
  • Strong research partnerships with China's leading genomics institutions
  • Located in Xi'an — SinomedTrip's home city, allowing seamless coordination from consultation through delivery

Frequently Asked Questions

What is PGT-Plus and how is it different from standard PGT genetic screening?

PGT-Plus is an advanced form of preimplantation genetic testing that screens embryos for a broader range of genetic conditions than standard PGT. While conventional PGT screens for specific known mutations (PGT-M) or chromosomal abnormalities (PGT-A), PGT-Plus combines multiple screening modalities to provide a more comprehensive genetic assessment of each embryo before transfer, increasing the chances of a healthy pregnancy.

Who should consider PGT-Plus during IVF treatment?

PGT-Plus is particularly valuable for couples with known genetic disorders in their family history, those who have experienced recurrent miscarriages or failed IVF cycles, and older parents where chromosomal abnormalities are more common. It is also recommended for couples who are both carriers of the same recessive genetic condition. The Tangdu fertility team can advise whether PGT-Plus is appropriate for your situation.

How much does IVF with PGT-Plus cost at Tangdu Hospital compared to other countries?

A complete IVF cycle with PGT-Plus at Tangdu Hospital typically costs $8,000 to $15,000, compared to $25,000 to $40,000 in the United States or $15,000 to $25,000 in Europe. This includes ovarian stimulation, egg retrieval, fertilization, genetic testing of embryos, and embryo transfer. The lower cost makes it feasible for couples to attempt multiple cycles if needed.

How long does the entire IVF with PGT-Plus process take at Tangdu Hospital?

The complete IVF cycle with PGT-Plus screening typically takes 4 to 6 weeks from initial consultation through embryo transfer. This includes ovarian stimulation over 10 to 14 days, egg retrieval, fertilization, embryo culture for 5 to 7 days, genetic screening which takes 2 to 3 weeks for results, and then embryo transfer. Some patients choose to freeze embryos and return for transfer in a subsequent cycle.

Can I use PGT-Plus if I am undergoing IVF at a clinic in my home country?

In some cases, embryo biopsy samples can be taken at your home clinic and shipped to a specialized genetics laboratory for PGT-Plus analysis. However, for the most integrated and quality-controlled experience, performing the entire IVF and PGT-Plus process at Tangdu Hospital is recommended. SinomedTrip can discuss both options with you during an initial consultation.


Considering IVF with advanced genetic screening? Request a free fertility consultation →

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.

Related Articles

A Father's 50-Kilogram Sacrifice: The Weight Loss Journey That Saved His Child's Life Through Kidney Donation

When doctors said his BMI was too high to donate a kidney to his dying child, this father lost 50 kilograms in months. A Shanghai hospital's multidisciplinary team then performed the living-donor transplant that gave his son a second chance at life.

Read More

A Bomb in Her Brain: The 12-Hour Surgery to Defuse a Giant Aneurysm That 90% of Hospitals Would Refuse

A young woman collapsed with the worst headache of her life. Scans revealed a massive cerebral aneurysm at the highest surgical grade. A Shanghai hospital's neurovascular team spent 12 hours dismantling it — and she walked out of the hospital.

Read More

World-First Trial: PUMCH Proves New Drug Combination Nearly Doubles Response Rates in Aplastic Anemia

PUMCH's hematology team published the first-ever randomized trial showing luspatercept plus cyclosporine achieves 79% response rates in non-transfusion-dependent aplastic anemia — nearly double the standard treatment, especially in elderly patients.

Read More

Not All Cervical Cancers Are Equal: PUMCH Research Shows Why Immunotherapy Works for Some Patients but Not Others

PUMCH's gynecologic oncology team published research revealing that cervical cancer subtypes have fundamentally different immune environments — explaining why PD-1 inhibitors work well for squamous cell carcinoma but fail in adenocarcinoma and neuroendocrine types.

Read More